S T Heijkoop1, R A Nout2, S Quint3, J W M Mens3, B J M Heijmen3, M S Hoogeman3. 1. Department of Radiation Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: s.heijkoop@erasmusmc.nl. 2. Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands. 3. Department of Radiation Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands.
Abstract
OBJECTIVE: For locally advanced cervical cancer patients, treated with External Beam Radiotherapy (EBRT), Quality of Life (QoL) questionnaires arefrequently used to evaluate treatment-related symptoms and functioning scales. Currently, it is unknown how those evolve during the radiation treatment course. In this prospective study we report on weekly-captured patient-reported QoL and symptoms during image-guided adaptive radiotherapy (IGART) of cervical cancer patients. MATERIAL AND METHODS: Between January 2012 and September 2016, all locally advanced cervical cancer patients treated with IGART and brachytherapy with or without chemotherapy or hyperthermia, were eligible. QoL was assessed at baseline; weekly during the first five weeks of treatment; 1week, 1 and 3months after treatment, using the EORTC QLQ-C30 and the QLQ-CX24 questionnaires. Comparisons were made with an age-matched norm population. RESULTS: Among the 138 (70%) responders, most symptoms showed a moderate-to-large increase, reaching a maximum at the end of treatment, or first week after treatment with return to baseline value at 3months after treatment. While most symptoms gradually increased during the first five weeks, diarrhea and bowel cramps already markedly increased within the first three weeks to reach a plateau at the 5th week of treatment. Global health and functioning were temporarily decreased and returned to a plateau at baseline level 3months after treatment, except for cognitive functioning. CONCLUSION: A profound impact on QoL was observed during the radiation treatment course, temporarily affecting functioning. The maximum impaired was reached at the end of EBRT.
OBJECTIVE: For locally advanced cervical cancerpatients, treated with External Beam Radiotherapy (EBRT), Quality of Life (QoL) questionnaires arefrequently used to evaluate treatment-related symptoms and functioning scales. Currently, it is unknown how those evolve during the radiation treatment course. In this prospective study we report on weekly-captured patient-reported QoL and symptoms during image-guided adaptive radiotherapy (IGART) of cervical cancerpatients. MATERIAL AND METHODS: Between January 2012 and September 2016, all locally advanced cervical cancerpatients treated with IGART and brachytherapy with or without chemotherapy or hyperthermia, were eligible. QoL was assessed at baseline; weekly during the first five weeks of treatment; 1week, 1 and 3months after treatment, using the EORTC QLQ-C30 and the QLQ-CX24 questionnaires. Comparisons were made with an age-matched norm population. RESULTS: Among the 138 (70%) responders, most symptoms showed a moderate-to-large increase, reaching a maximum at the end of treatment, or first week after treatment with return to baseline value at 3months after treatment. While most symptoms gradually increased during the first five weeks, diarrhea and bowel cramps already markedly increased within the first three weeks to reach a plateau at the 5th week of treatment. Global health and functioning were temporarily decreased and returned to a plateau at baseline level 3months after treatment, except for cognitive functioning. CONCLUSION: A profound impact on QoL was observed during the radiation treatment course, temporarily affecting functioning. The maximum impaired was reached at the end of EBRT.
Authors: L M Wiltink; M King; F Müller; M S Sousa; M Tang; A Pendlebury; J Pittman; N Roberts; L Mileshkin; R Mercieca-Bebber; M-A Tait; R Campbell; C Rutherford Journal: Support Care Cancer Date: 2020-06-18 Impact factor: 3.603
Authors: Karen M Gil; Stephanie L Pugh; Ann H Klopp; Anamaria R Yeung; Lari Wenzel; Shannon N Westin; David K Gaffney; William Small; Spencer Thompson; Desiree E Doncals; Guilherme H C Cantuaria; Brian P Yaremko; Amy Chang; Vijayananda Kundapur; Dasarahally S Mohan; Michael L Haas; Yong Bae Kim; Catherine L Ferguson; Snehal Deshmukh; Lisa A Kachnic; Deborah W Bruner Journal: Gynecol Oncol Date: 2019-05-16 Impact factor: 5.482
Authors: Yvette Seppenwoolde; Katarina Majercakova; Martin Buschmann; Elke Dörr; Alina E Sturdza; Maximilian P Schmid; Richard Pötter; Dietmar Georg Journal: Strahlenther Onkol Date: 2021-04-30 Impact factor: 3.621